National Research Correlations
NRC Stock | USD 14.68 0.24 1.66% |
The current 90-days correlation between National Research Corp and Omega Flex is 0.33 (i.e., Weak diversification). The correlation of National Research is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
National Research Correlation With Market
Weak diversification
The correlation between National Research Corp and DJI is 0.35 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding National Research Corp and DJI in the same portfolio, assuming nothing else is changed.
National |
Moving together with National Stock
0.67 | ELMD | Electromed | PairCorr |
0.87 | XAIR | Beyond Air | PairCorr |
0.73 | HOLX | Hologic | PairCorr |
0.77 | ICUI | ICU Medical | PairCorr |
0.75 | INFU | InfuSystems Holdings | PairCorr |
0.81 | LIVN | LivaNova PLC | PairCorr |
0.62 | PAVMZ | PAVmed Series Z | PairCorr |
0.74 | SSKN | STRATA Skin Sciences Earnings Call Tomorrow | PairCorr |
0.72 | TELA | Tela Bio | PairCorr |
0.61 | CLPT | Clearpoint Neuro | PairCorr |
0.69 | CDIOW | Cardio Diagnostics | PairCorr |
0.65 | VINC | Vincerx Pharma Earnings Call This Week | PairCorr |
0.73 | VRDN | Viridian Therapeutics | PairCorr |
0.7 | ELEV | Elevation Oncology | PairCorr |
0.69 | ELVN | Enliven Therapeutics | PairCorr |
0.75 | WINT | Windtree Therapeutics Buyout Trend | PairCorr |
Moving against National Stock
0.69 | LUNG | Pulmonx Corp Downward Rally | PairCorr |
0.67 | ACONW | Aclarion | PairCorr |
0.66 | LUCD | Lucid Diagnostics | PairCorr |
0.59 | INMD | InMode | PairCorr |
0.54 | PEN | Penumbra | PairCorr |
0.64 | NURO | NeuroMetrix | PairCorr |
0.56 | MNDR | Mobile health Network | PairCorr |
0.31 | TMDX | TransMedics Group | PairCorr |
0.84 | GILD | Gilead Sciences Sell-off Trend | PairCorr |
0.81 | GSK | GlaxoSmithKline PLC ADR | PairCorr |
0.79 | AZN | AstraZeneca PLC ADR | PairCorr |
0.78 | NVS | Novartis AG ADR | PairCorr |
0.76 | OCX | OncoCyte Corp | PairCorr |
0.75 | SNY | Sanofi ADR | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between National Stock performing well and National Research Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze National Research's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
OFLX | 1.77 | (0.18) | 0.00 | (0.53) | 0.00 | 3.01 | 9.64 | |||
NXGN | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
NODK | 1.16 | (0.20) | 0.00 | (0.32) | 0.00 | 2.11 | 9.93 | |||
CNXN | 1.26 | (0.19) | 0.00 | (0.39) | 0.00 | 1.85 | 13.92 | |||
NRIM | 1.63 | (0.12) | 0.00 | (0.17) | 0.00 | 2.44 | 9.90 |
National Research Corporate Management
CPA CPA | CFO, Fin | Profile | |
Jennifer Baron | Chief Officer | Profile | |
Gregory MS | Chief Officer | Profile | |
Linda Stacy | Principal Officer | Profile | |
Jona Raasch | Chief Officer | Profile | |
Jon Boumstein | Chief Officer | Profile |